Gilead Sciences, Inc. (GILD) Stock Price & Analysis
Gilead Sciences, Inc. (GILD) closed at USD 157.19 on Thursday, October 22, 2026, up 2.36% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 157.19; the Oct 22, 2026 session ranged USD 153–157.42 on volume of 6,210,290 shares. Market capitalization is —, with a 52-week range of USD 114.02–160.51 (NMS). Source: Nexqual, retrieved October 23, 2026 at 09:28 UTC.
Also available as compact Markdown for AI agents: nexqual.com/GILD.md
Key facts (GILD)
- Last four reported quarters (through Jun 30, 2026): revenue $30.5B, net income -$3.24B (-10.6% margin), free cash flow $12.9B (SEC filings).
- 3 of 80 tracked superinvestors hold GILD (13F, Q2 2026): 0 new, 0 added, 2 reduced, 1 unchanged.
- Total return with dividends: 1Y +33.4% vs S&P 500 +14.9%; 5Y +179.3% vs S&P 500 +80.3%.
- Next earnings: 2026-10-29, EPS estimate USD 2.2, revenue estimate $7.81B.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (GILD)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $27.3B | $27.3B | $27.1B | $28.8B | $29.4B | $30.5B |
| Gross profit | $20.7B | $21.6B | $20.6B | $22.5B | $23.2B | — |
| Operating income | $9.92B | $7.33B | $7.61B | $1.66B | $10.0B | -$2.50B |
| Net income | $6.22B | $4.59B | $5.67B | $480M | $8.51B | -$3.24B |
| EPS (diluted) | $4.93 | $3.64 | $4.50 | $0.38 | $6.78 | — |
| Free cash flow | $10.8B | $8.34B | $7.42B | $10.3B | $9.46B | $12.9B |
| Gross margin | 75.8% | 79.3% | 76.0% | 78.3% | 78.8% | — |
| Operating margin | 36.3% | 26.9% | 28.0% | 5.8% | 34.0% | -8.2% |
| Net margin | 22.8% | 16.8% | 20.9% | 1.7% | 28.9% | -10.6% |
| Revenue growth | +10.6% | -0.1% | -0.6% | +6.0% | +2.4% | — |
| Cash + short-term investments | $6.52B | $6.38B | $7.26B | $9.99B | $7.63B | — |
| Total debt | $26.7B | $25.2B | $25.0B | $26.7B | $24.9B | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (GILD)
P/S 6.4x · EV/Sales 7.2x · P/FCF 15.1x · P/B 16.5x · FCF yield 6.64% · Earnings yield -1.66% · Dividend yield (paid, TTM) 2.09% · Buyback yield (TTM) 0.74% · Net debt $23.1B · EV $218B
P/E at fiscal year-ends: Dec 2025 18.1x, Dec 2024 241.5x, Dec 2023 18.0x.
Superinvestors (SEC 13F-HR, Q2 2026) (GILD)
3 of 80 tracked investors hold GILD. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| Dodge & Cox Funds | Dodge & Cox | 1.57% | $2.99B | Reduced -2.4% |
| John Rogers | Ariel Investments | 0.25% | $24.7M | Reduced -3.3% |
| Mairs & Power | Mairs & Power Funds | <0.01% | $287K | Unchanged |
Analysts (GILD)
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-20 | B of A Securities | Target raised | Buy | $168 → $172 |
| 2026-10-08 | RBC Capital | Target raised | Sector Perform | $123 → $126 |
| 2026-10-08 | Cantor Fitzgerald | Reiterated | Overweight | $155 |
| 2026-10-07 | Truist Securities | Target raised | Buy | $150 → $158 |
| 2026-10-07 | JP Morgan | Target raised | Overweight | $160 → $170 |
| 2026-10-07 | Morgan Stanley | Target lowered | Overweight | $165 → $163 |
| 2026-09-10 | HSBC | Target raised | Buy | $155 → $175 |
| 2026-08-05 | RBC Capital | Target raised | Sector Perform | $120 → $123 |
| 2026-08-05 | Cantor Fitzgerald | Reiterated | Overweight | $155 |
| 2026-08-05 | Needham | Reiterated | Buy | $170 |
| 2026-07-29 | Barclays | Target lowered | Equal-Weight | $155 → $145 |
| 2026-07-27 | Morgan Stanley | Target lowered | Overweight | $166 → $165 |
Total return (dividends reinvested) (GILD)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-18) | |
|---|---|---|
| Total return | +33.4% | +179.3% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +33.5% | +22.8% |
| Volatility (annualized) | 26.7% | 23.8% |
| Max drawdown | -21.6% (Feb 2026→Jun 2026) | -25.6% (Jan 2024→May 2024) |
Companies that name GILD in their SEC reports
| Relationship to GILD | Company | Filing | Sentence |
|---|---|---|---|
| partner | Kyverna Therapeutics, Inc. (KYTX) | 10-K Mar 26, 2026 | “In January 2020, the Company entered into the Collaboration, Option and License Agreement (the "Gilead Agreement") with Gilead Sciences, Inc. ("Gilead").” |
| supplier | VEEVA SYSTEMS INC (VEEV) | 10-K Mar 20, 2026 | “Our life sciences customers range from the largest global pharmaceutical and biotechnology companies such as Bayer AG, Boehringer Ingelheim GmbH, Eli Lilly and Company, Gilead Sciences, Inc., Merck Sharp & Dohme Corp., and Novartis Pharma AG, to emerging growth pharmaceutical and biotechnology companies, including Alkermes Inc., Alnylam Pharmaceuticals, Inc., bluebird bio, Inc., and Idorsia Pharmaceuticals Ltd. We…” |
| partner | Cellectis S.A. (CLLS) | 20-F Mar 20, 2026 | “Autologous and Allogeneic CAR T-cell space: Bristol-Myers Squibb, Gilead Sciences Inc., Novartis AG, Johnson & Johnson, Regeneron Pharmaceuticals Inc., Fate Therapeutics Inc., CRISPR Therapeutics Inc., Caribou Biosciences Inc., Takeda Pharmaceutical Company Limited, Mustang Bio, Atara Biotherapeutics Inc., Adaptimmune (in collaboration with Astellas), Poseida Therapeutics Inc. (acquired by F.” |
| partner | ASSEMBLY BIOSCIENCES, INC. (ASMB) | 10-K Mar 19, 2026 | “our ability to realize the potential benefits of our collaboration with Gilead Sciences, Inc. (Gilead), including all financial aspects of the collaboration and equity investments;” |
| partner | Gossamer Bio, Inc. (GOSS) | 10-K Mar 17, 2026 | “Pursuant to the terms of the license agreement with Pulmokine, Gilead Sciences and the Rensselaer Center for Translational Research, Inc., the licensors may have the right to control enforcement of our licensed patents or defense of any claims asserting the invalidity of these patents and even if we are permitted to pursue such enforcement or defense, we will require the cooperation of our licensors.” |
| partner | AGENUS INC (AGEN) | 10-K Mar 16, 2026 | “For example, in February 2015, we began a broad collaboration with Incyte to pursue the discovery and development of antibodies, in December 2018 we entered into a partnership with Gilead relating to five of our antibody programs and in May 2021 we entered into a license agreement with BMS relating to our anti-TIGIT bispecific antibody” |
| partner | MACROGENICS INC (MGNX) | 10-K Mar 9, 2026 | “We are also collaborating with Gilead Sciences, Inc. (Gilead) on the development of MGD024, a bispecific DART molecule targeting CD123 and CD3 that utilizes our next-generation T-cell engager technology, as well as two additional undisclosed pre-clinical DART and TRIDENT molecule development programs.” |
| partner | Tango Therapeutics, Inc. (TNGX) | 10-K Mar 5, 2026 | “For some of our product candidates, we may decide to collaborate with other pharmaceutical and biotechnology companies, like our existing collaboration with Gilead, for the development and potential commercialization of those product candidates.” |
| partner | Kymera Therapeutics, Inc. (KYMR) | 10-K Feb 26, 2026 | “In June 2025, we announced a strategic collaboration with Gilead Sciences, Inc. ("Gilead") to develop novel oral molecular glue degraders for CDK2.” |
| partner | Arcus Biosciences, Inc. (RCUS) | 10-K Feb 25, 2026 | “•We expect to depend on our collaboration with Gilead for the research, development, manufacture and commercialization of certain of our investigational products.” |
| partner | Xencor Inc (XNCR) | 10-K Feb 25, 2026 | “In January 2020, the Company entered into a Technology License Agreement (the "Gilead Agreement") with Gilead, pursuant to which the Company granted Gilead an exclusive license to its Cytotoxic Fc and Xtend Fc technologies for an initial identified antibody and options for up to three additional antibodies directed to the same molecular target.” |
| customer | IDEAYA Biosciences, Inc. (IDYA) | 10-K Feb 17, 2026 | “our ability to maintain existing, and establish new, strategic collaborations, licensing or other arrangements and the financial terms of any such agreements, including our Clinical Study Collaboration and Supply Agreement with Gilead Sciences, Inc. (Gilead), our Clinical Trial Collaboration and Supply Agreements with Pfizer Inc. (Pfizer), our License Agreement with Novartis, our Option and License Agreement with …” |
| partner | Nurix Therapeutics, Inc. (NRIX) | 10-K Jan 28, 2026 | “Our partnered drug discovery pipeline consists of a clinical stage degrader of IRAK4 (NX-0479/GS-6791), a preclinical stage degrader of STAT6, currently in investigational new drug application (IND), enabling studies, and multiple currently undisclosed targets under collaboration agreements with Gilead Sciences, Inc. (Gilead), Sanofi S.A. (Sanofi) and Pfizer Inc. (Pfizer).” |
GILD analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $2.20 | $2.21 | -0.1% | $7.81B | 22 |
| Next quarter (ends Dec 2026) | $2.16 | $2.26 | -4.3% | $8.20B | 20 |
| Current fiscal year (ends Dec 2026) | $-0.40 | $-0.77 | -48.1% | $30.78B | 27 |
| Next fiscal year (ends Dec 2027) | $9.98 | $9.63 | +3.6% | $32.90B | 26 |
Key Statistics (as of October 23, 2026 at 09:28 UTC)
| Price | USD 157.19 |
|---|---|
| Change | ▲ 2.36% (up) |
| Previous Close | USD 157.19 |
| Open | USD 157.19 |
| Day Range | USD 153 – 157.42 |
| 52-Week Range | USD 114.02 – 160.51 |
| Volume | 6,210,290 shares |
| Market Cap | — |
| Exchange | NMS |
Technical Analysis (GILD)
Nexqual's technical model rates GILD "BUY" based on 5 bullish and 1 bearish signals across 127 daily candles, as of October 23, 2026 at 09:28 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 59 (neutral) |
| vs SMA50 | Above (USD 148.48) |
| MACD | 2.35 (positive) |
Earnings (GILD)
| Next Earnings Date | 2026-10-29 |
|---|---|
| EPS Estimate | USD 2.2 |
| Revenue Estimate | $7.81B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -6.75 vs est -7.25 ▲ beat |
| 2026-03-31 | USD 2.03 vs est 1.91 ▲ beat |
| 2025-12-31 | USD 1.86 vs est 1.81 ▲ beat |
| 2025-09-30 | USD 2.47 vs est 2.14 ▲ beat |
Source: Nexqual, October 23, 2026 at 09:28 UTC.
Financials & Fundamentals (GILD)
| Total Revenue | $30.46B |
|---|---|
| Revenue Growth (latest quarter, YoY) | +10.20% |
| Gross Margin | +79.60% |
| Operating Margin | +33.68% |
| Profit Margin | -10.64% |
| ROE | -20.68% |
| Debt / Equity | 2.23 |
| Current Ratio | 1.27 |
| Total Cash | $4.88B |
| Total Debt | $26.25B |
Source: Nexqual, October 23, 2026 at 09:28 UTC.
Ownership (GILD)
| Insider Ownership | +0.11% |
|---|---|
| Institutional Ownership | +92.01% |
| Shares Outstanding | 1.24B |
| Float | 1.24B |
| Short % of Float | +1.76% |
Source: Nexqual, October 23, 2026 at 09:28 UTC.
Leadership (GILD)
Gilead Sciences, Inc. is led by Daniel Patrick O'Day, Chairman & CEO, per Nexqual as of October 23, 2026 at 09:28 UTC.
| Chairman & CEO | Daniel Patrick O'Day |
|---|---|
| Executive VP & CFO | Andrew D. Dickinson |
| Senior Vice President of Treasury & Investor Relations | Jacquie Ross C.F.A. |
| Executive Vice President of Human Resources | Jyoti K. Mehra |
| Senior Vice President of Research, Innovation & Portfolio | Linda Slanec Higgins |
Major Backers & Investors (GILD)
Notable institutional backers of Gilead Sciences, Inc. include FMR, LLC, Capital Group, Invesco, according to Nexqual as of October 23, 2026 at 09:28 UTC.
Active Investors
| Investor | Stake |
|---|---|
| FMR, LLC | 5.39% |
| Capital Group | 3.31% |
| Invesco | 3.21% |
| Price (T.Rowe) Associates Inc | 2.42% |
| Morgan Stanley | 1.94% |
| Dodge & Cox Funds-Dodge & Cox Stock Fund | 1.39% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 9.83% |
| Vanguard Group | 9.39% |
| State Street | 4.94% |
| Geode Capital | 2.42% |
Source: Nexqual, October 23, 2026 at 09:28 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| NVO | Novo Nordisk A/S | USD 39.43 | ▲ 0.95% |
| PFE | Pfizer, Inc. | USD 30.42 | ▲ 1.91% |
| AMGN | Amgen Inc. | USD 447.28 | ▲ 2.04% |
| AZN | AstraZeneca PLC | USD 172.57 | ▲ 2.45% |
| BMY | Bristol-Myers Squibb Company | USD 63 | ▲ 3.08% |
| NVS | Novartis AG | USD 156.27 | ▲ 1.52% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 09:28 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt